Drug Topics
AUGUST 24, 2023
The Modernizing and Ensuring PBM Accountability Act, recently passed by the Senate Finance Committee, aims to regulate PBMs in the Medicare Part D, Medicare Advance, and Medicaid spaces.
Pharmacy Times
AUGUST 24, 2023
Notably, 65% of the participants experiencing pain at the 2-month follow up were also experiencing pain at their 12-month follow up, suggesting persistent and long-term pain.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
AUGUST 24, 2023
A greater number of pharmacy audits are originating not only from third party payors, but also from various government agencies, such as Medicare and Medicaid.
Pharmacy Times
AUGUST 24, 2023
UB-311 has shown to be well-tolerated with a durable antibody response in a previous phase 1 trial, and new results from a phase 2a study support its continued development.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
AUGUST 24, 2023
A new study found that 34% of the chatbot’s answers included 1 or more recommendation that did not align with clinical guidelines.
Pharmacy Times
AUGUST 24, 2023
The phase 3 study will advance the safety findings of survodutide reported in the phase 2 study to aid overweight and obesity.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
AUGUST 24, 2023
The drug is the first approved antiviral COVID-19 treatment that could be used across all stages of liver disease.
Fierce Pharma
AUGUST 24, 2023
Just a few short weeks after Wegovy posted a major cardio outcomes win, Novo Nordisk has chalked up another heart-related victory for its semaglutide star. | In a phase 3 study, semaglutide at the 2.4 mg dose bested placebo at reducing symptoms and physical limitations in patients with obesity and heart failure with preserved ejection fraction. The drug also led to greater improvements in exercise function and more weight loss versus a dummy drug, according to study results published in The New
The FDA Law Blog
AUGUST 24, 2023
Hyman, Phelps & McNamara, P.C. (“HP&M”) is is proud to announce that 14 of the Firm’s attorneys have been selected to the 2024 edition of The Best Lawyers in America®. Newly recognized this year are attorneys Josephine M. Torrente (FDA Law), Michelle L. Butler (FDA Law), Sara W. Koblitz (FDA Law), Allyson B. Mullen (FDA Law), and Anne K. Walsh (FDA Law), as well as McKenzie E.
The Checkup by Singlecare
AUGUST 24, 2023
Maybe you’ve heard that acidophilus is excellent for your gut health. Or perhaps a friend has recommended it as an immunity booster for fighting the cold or flu. The truth is that acidophilus—a beneficial bacteria found in your body, certain foods, and most probiotic supplements —has many health benefits. L. acidophilus probiotics can help your body in several ways, including aiding in weight loss, reducing cholesterol levels, and helping to treat vaginal infections.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Pharma
AUGUST 24, 2023
It's not always a good thing when a drug developer stops a cancer trial. But in a recent case for Exelixis, a Cabometyx trial ended early because of an undeniable efficacy showing. | Exelixis' drug proved its worth in treating advanced pancreatic and extra-pancreatic neuroendocrine tumors, so much so that an independent board unanimously recommended an early stop.
Hospital Pharmacy Europe
AUGUST 24, 2023
A birch bark extract has been recommended by NICE for treating skin wounds associated with dystrophic and junctional epidermolysis bullosa. In the UK, draft guidance from NICE has recommended a birch bark extract within its marketing authorisation, as an option for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.
STAT
AUGUST 24, 2023
In Igbo-Nigerian culture, new moms receive exquisite care from their own mothers, mothers-in-law, or surrogate mothers for the first few months postpartum. After each of my daughters was born, I was blessed to participate in this tradition, called omugwo, which allowed me to be nurtured by the mothers who came before me. They cooked and cleaned. Massaged my belly and taught me how to breastfeed.
Fierce Healthcare
AUGUST 24, 2023
A new value-based care agreement has been announced between Humana and Interwell Health, a kidney care management company, in 13 states. | Humana and Interwell Health, a kidney care management company, have partnered to begin a new value-based care agreement to certain Medicare Advantage members in 13 states.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
AUGUST 24, 2023
Royalty Pharma has built a niche by finding innovative products pre- and post-approval from companies that need an infusion of cash in exchange for future royalties. | Royalty Pharma has signed a deal with Ferring Pharmaceuticals to collect royalties on bladder cancer drug Adstiladrin. Royalty will pay $300 million up front and $200 million in a potential milestone tied to Ferring meeting certain manufacturing goals.
Fierce Healthcare
AUGUST 24, 2023
Though hospitals’ patient experience scores broadly suffered during the COVID-19 pandemic, the “unprecedented” declines were greatest among facilities that were already facing staffing issues prior | Patient experience score declines were steepest among facilities already understaffed or poorly rated, though no hospital exited 2021 with their HCAHPS scores unscathed, according to a new CMS-backed analysis.
Fierce Pharma
AUGUST 24, 2023
Moderna is considering pairing one of its mRNA cancer vaccine candidates with a CAR-T therapy from China's CARsgen. GSK's Shingrix showed 100% efficacy in a postmarketing trial in China. | Moderna is considering pairing an mRNA cancer vaccine candidate with a CAR-T therapy from China's CARsgen. GSK's Shingrix showed 100% efficacy in a Chinese post-marketing trial.
European Pharmaceutical Review
AUGUST 24, 2023
GSK’s Shingrix (Recombinant Zoster Vaccine or RZV) vaccine has been shown to offer 100 percent efficacy against shingles in adults 50 years old and over in China. The Phase IV trial (ZOSTER-076) is the first-ever efficacy trial of the shingles vaccine Shingrix in China. Almost 6,000 participants were enrolled in the trial, which was conducted between 2021 and 2023.
Fierce Pharma
AUGUST 24, 2023
After the “extreme disappointment” of vadadustat’s anemia snub in March 2022—plus a partnership gone awry and a formal dispute with the FDA—Akebia Therapeutics has dusted itself off and readied for | After the “extreme disappointment” of vadadustat’s anemia snub in March 2022—plus a partnership gone awry and a formal dispute with the FDA—Akebia Therapeutics has dusted itself off and readied for a second bid at approval.
STAT
AUGUST 24, 2023
The news that the weight loss drug Wegovy reduced the risk of heart attacks and strokes in overweight volunteers opens up the door to vastly expanded use of the drug and medicines like it, known as GLP-1 inhibitors. That could have a big, positive impact on public health, and it will very likely swell the coffers of the pharmaceutical companies that make these medicines, including Wegovy’s maker, Novo Nordisk, and Eli Lilly, now the most valuable drug company in history thanks largely to
Drug Store News
AUGUST 24, 2023
The moves follows Aldi's definitive agreement to acquire Winn-Dixie and Harveys Supermarket as part of a larger divestiture of Southeastern Grocers to various entities.
STAT
AUGUST 24, 2023
It’s almost a tradition. At the start and halfway points of each year, many pharmaceutical companies raise drug prices to bolster revenue and reportedly fund new research. “It’s not just all selling new drugs,” said Juliette Cubanski, deputy director of the Program on Medicare Policy at Kaiser Family Foundation. “It’s increasing prices on their existing portfolio.
Pharmaceutical Technology
AUGUST 24, 2023
The newly-launched business, called Corvardis, is already targeting the Humira biosimilar landscape with Hyrimoz via a planned Sandoz-partnered launch in Q1 2024.
Hospital Pharmacy Europe
AUGUST 24, 2023
Talquetamab has been granted a conditional marketing authorisation by the European Commission as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma. Talquetamab (brand name Talvey) is approved as a weekly or biweekly subcutaneous injection after an initial step-up phase. It can be used as monotherapy for the treatment of patients relapsed and refractory multiple myeloma who have had an inadequate response to at least three prior therapies, including an
STAT
AUGUST 24, 2023
U.S. News & World Report recently issued its 2023-24 Best Hospitals ratings. The ratings come at a time of increased scrutiny and skepticism of ranking systems. In very public ways, many colleges, law schools, and medical schools have declined to participate in the U.S. News process, while some hospitals have expressed their desire to abandon the rankings as well.
European Pharmaceutical Review
AUGUST 24, 2023
A new drug formulation of a protein kinase inhibitor therapeutic designed to modify the course of Parkinson’s diseas e has been developed. The Abelson Tyrosine Kinase (c-Abl) inhibitor risvodetinib (IkT-148009), “nearly doubles” drug exposure, according to Inhibikase Therapeutics’ CEO. Dr Milton Werner, President & CEO of Inhibikase explained that the company “recently completed characterisation of a novel tablet formulation that mimics the oral drug formulation we used to evaluate eff
Fierce Pharma
AUGUST 24, 2023
As the Federal Trade Commission tries to block Amgen’s $28 billion acquisition of Horizon Therapeutics with an injunction, Amgen has a lot to say in court filings. | The Federal Trade Commission is trying to block Amgen’s proposed $28 billion acquisition of Horizon Therapeutics. Amgen has a lot to say as the case plays out in court.
BioPharm
AUGUST 24, 2023
Royalty Pharma agreed to spend up to $500 million for a 5.1 to 8% royalty on net sales of Ferring’s gene therapy adstiladrin (nadofaragene firadenovec-vcng).
Hospital Pharmacy Europe
AUGUST 24, 2023
An oral, delayed-release budesonide formulation provides a clinically relevant reduction in estimated glomerular filtration rate (eGFR) decline and a durable reduction in proteinuria versus placebo in patients with primary IgA nephropathy (IgAN), a new study has shown. The the first and only treatment indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, budesonide was approved by the FDA in 2021 under the accelerated approval scheme.
Pharmaceutical Technology
AUGUST 24, 2023
Dizal has received approval from China’s NMPA for sunvozertinib to treat adult patients with locally advanced or metastatic NSCLC
Drug Store News
AUGUST 24, 2023
As its first product, Cordavis has contracted with Sandoz to commercialize and bring to market Hyrimoz, a biosimilar for Humira.
Pharmaceutical Technology
AUGUST 24, 2023
Japan has granted a new drug substance patent for BioArctic’s monoclonal antibody (mAb), BAN0805, to treat Parkinson’s disease.
Outsourcing Pharma
AUGUST 24, 2023
FORE Biotherapeutics yesterday (August 23) announced the closing of its $75 million (Â59 million) series D financing, led by the SR One and co-led by Medicxi and joined by existing investors.
PharmaVoice
AUGUST 24, 2023
New variants drive a need for another round of shots, and biopharma companies are stepping up to the plate.
Expert insights. Personalized for you.
186 
Let's personalize your content